Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia
Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia. A Case-control Trial Nested in a Cohort
Fondation Ophtalmologique Adolphe de Rothschild
200 participants
Mar 19, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.
Eligibility
Inclusion Criteria8
- \- For cases, admitted within the first 36 hours of an acute neurological symptom related to :
- An ischaemic cerebrovascular accident (iCVA) eligible for a mechanical thrombectomy procedure,
- A subarachnoid haemorrhage (SAH, all aetiologies) : patient presenting with at least a modified Fisher scale 3 or 4,
- An intra-parenchymal haematoma (IPH) with greatest axis ≥ 20mm or with NIHSS on admission >4.
- OR
- For control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (TIA) - based on thorough questioning of the patient on admission - and prior to imaging, with an ABCD2≥ 2 score.
- Express consent to participate in the study.
- Member or beneficiary of a social security.
Exclusion Criteria8
- Pre-existing functional and/or cognitive disability
- Patient under legal protection.
- Pregnant or breastfeeding woman.
- Patient with secondary haemorrhagic transformation.
- Patients with an ischaemic lesion visible on imaging, unrelated to large vessel occlusion and therefore ineligible for mechanical thrombectomy.
- Patients diagnosed with an acute non-vascular neurological pathology (migraine, epilepsy, etc.).
- TIA patients presenting an abnormality on follow-up imaging 24-48 hours after the initial imaging.
- Excluded patients will be replaced.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04971564